Chng, W-J
Goldschmidt, H
Dimopoulos, M A
Moreau, P
Joshua, D
Palumbo, A
Facon, T
Ludwig, H
Pour, L
Niesvizky, R
Oriol, A
Rosiñol, L
Suvorov, A
Gaidano, G
Pika, T
Weisel, K
Goranova-Marinova, V
Gillenwater, H H
Mohamed, N
Feng, S
Aggarwal, S
Hájek, R
Article History
Received: 21 September 2016
Revised: 23 November 2016
Accepted: 5 December 2016
First Online: 27 December 2016
Competing interests
: The ENDEAVOR study was supported by Onyx Pharmaceuticals, Inc., an Amgen subsidiary. HG played a consulting or advisory role in Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Millennium Pharmaceuticals, Novartis and Onyx Pharmaceuticals; received honoraria from Celgene Corporation, Chugai, Janssen Pharmaceuticals, Millennium Pharmaceuticals, Novartis and Onyx Pharmaceuticals and received research funding from Bristol-Myers Squibb, Celgene Corporation, Chugai, Janssen Pharmaceuticals and Novartis. MAD received honoraria from Celgene and Onyx and played a consulting or advisory role in Celgene and Onyx. PM played a consulting or advisory role in Celgene, Janssen, Millennium, Novartis and Onyx, and received honoraria from Celgene, Janssen, Millennium, Novartis and Onyx. DJ participated in a Speakers’ bureau for Amgen. W-JC received honoraria from Celgene, Janssen, Novartis and Takeda and received research funding from Celgene, Novartis and Merck. AP is an employee of Takeda; has received honoraria from and served as consultant for Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis and Merck; has received research funding from Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis, Merck and Binding Site; and participated in a speakers’ bureau for Bristol-Myers Squibb. TF has served on a advisor committee for Onyx/Amgen. HL participated in a Speakers’ bureau for Amgen, Bristol-Myers Squibb, Celgene, Novartis and Takeda and received study support from Takeda. RN played a consulting or advisory role in Celgene, Millennium and Onyx and participated in a Speakers’ bureau for Celgene, Millennium and Onyx. AO played a consulting or advisory role in Amgen, Celgene and Janssen and participated in a Speakers’ bureau for Amgen, Celgene and Janssen. LR received honoraria from Amgen, Celgene and Janssen. GG received honoraria from Amgen, Roche, Janssen, Gilead, Karyopharm and Morphosys, and played a consulting or advisory role in Amgen, Roche, Janssen, Gilead, Karyopharm and Morphosys. KW received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Onyx and Takeda and played a consulting or advisory role in Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Onyx and Takeda. HHG and NM were formerly employed by Onyx Pharmaceuticals, an Amgen subsidiary. SA and SF are employees of Amgen. RH received honoraria from Celgene, Janssen, Merck, Onyx and Amgen. The remaining authors declare no conflict of interest.